This is a preview of subscription content, log in via an institution to check access.
Reference
Li C, et al. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study. PLOS Medicine : 4 Mar 2021. Available from: URL: https://doi.org/10.1371/journal.pmed.1003515
Rights and permissions
About this article
Cite this article
Intensive antihypertensive treatment saves lives at acceptable cost in China. PharmacoEcon Outcomes News 875, 16 (2021). https://doi.org/10.1007/s40274-021-7595-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7595-1